Savara (SVRA) risk factors

Item 1A of every Savara Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open SVRA in Gloom →

Savara's chart, financials and news, free in your browser.Open SVRA in Gloom →

FY2025 10-K risk factors
44 risks3 new2 dropped7 reworded
Savara updated debt obligations with a new Hercules Capital loan facility and expanded data privacy and healthcare compliance disclosures.
Filed Mar 13, 2026
FY2024 10-K risk factors
43 risks
Savara relies entirely on the clinical, regulatory, and commercial success of its sole product candidate, MOLBREEVI, for aPAP. The company faces significant risks regarding capital requirements, regulatory approvals, third-party reimbursement, and lack of issued patents for MOLBREEVI.
Filed Mar 27, 2025